By Ross Youngs,  July 26, 2025 A New Paradigm for Accredited Investors: Equity vs. Direct Asset Tokenization Impact for funding under Reg D by the Newly Approved National Legislation Abstract Drug discovery productivity—measured as clinically viable new molecules per research has declined for decades, a trend known as Eroom’s Law. This paradox persists despite advances in screening, computing, and artificial

By Ross Youngs, September 23, 2025 The Evolutionary Advantage: Why Microbial Chemistry Wins in Drug Discovery & Approval Quantifying Success and Capitalized Cost Savings from Lead Identification Executive Summary The classic ‘magic‐bullet’ strategy—maximally selective ligands for single targets—is well suited to simple causal architectures but less effective for diseases driven by robust and redundant networks (e.g., cancer, metabolic and neurodegenerative disorders).